Table 1.
Baseline characteristics of individuals tested positive for SARS-COV-2 infection by rt-PCR test and Propensity Score–Matched control participants who tested negative for SARS-COV-2 infection.
Fig 1.
Estimates Vaccine effectiveness of inactivated vaccine BBIBP-CorV against COVID-19-associated severe or critical hospitalization according to vaccination status and by time since vaccination.
Fig 2.
Vaccine Effectiveness of inactivated vaccine BBIBP-CorV against COVID-19-associated severe or critical hospitalization over time since second dose vaccination.
Vaccine Effectiveness at each Time Point: At (1–30) time point; VE 88% (95% CI: 84–91), At (31–60) time point; 87% (95% CI: 83–90), At (61–90) time point; 87% (95% CI: 83–90), At (91–120) time point; 75% (95% CI: 67–80), At (121–150) time point; 61% (95% CI: 54–67), Beyond 150 days’ time point; 64% (95% CI: 59–69).
Fig 3.
Vaccine effectiveness of inactivated vaccine BBIBP-CorV against COVID-19-associated severe or critical hospitalization over time since second dose vaccination according to age subgroup.
Vaccine Effectiveness at each Time Point in age subgroup ≥ 60 years old: VE at (1–30) time point; 80% (95% CI: 80–94).VE at (31–60) time point; 85% (95% CI: 76–91). VE at (61–90) time point; 87% (95% CI: 78–92). VE at (91–120) time point; 64% (95% CI: 48–75). VE at (121–150) time point; 53% (95% CI: 42–61). VE Beyond 150 days’ time point; 66% (95% CI: 59–70). Vaccine Effectiveness at each time point in age subgroup < 60 years old: VE at (1–30) time point; 88% (95% CI: 82–92). VE at (31–60) time point; 90% (95% CI: 85–93). VE at (61–90) time point; 90% (95% CI: 85–93). VE at (91–120) time point; 84% (95% CI: 74–90). VE at (121–150) time point; 72% (95% CI: 60–80). VE Beyond 150 days’ time point; 70% (95% CI: 57–79).
Fig 4.
Estimates Vaccine effectiveness of inactivated vaccine BBIBP-CorV against COVID-19-associated severe or critical hospitalization according to age and gender over time since second dose vaccination.